Current Pain and Headache Reports

, Volume 8, Issue 5, pp 393–398

Post-triptan era for the treatment of acute migraine

  • Peter J. Goadsby

DOI: 10.1007/s11916-996-0013-3

Cite this article as:
Goadsby, P.J. Current Science Inc (2004) 8: 393. doi:10.1007/s11916-996-0013-3


There now is one realized and several attractive targets for the treatment of acute attacks of migraine that will follow and augment the use of serotonin 5-HT1B/1D receptor agonists, the triptans. Calcitonin gene-related peptide (CGRP) receptor blockade recently has been shown to be an effective acute antimigraine strategy; therefore, blockade of CGRP release by inhibition of trigeminal nerves would seem a logical approach. A number of targets are reviewed in this article including serotonin 5-HT1F and 5-HT1D receptors, adenosine A1 receptors, nociceptin, vanilloid TRPV1 receptors, and anandamide CB1 receptors. Development of one or more such compound offers the exciting prospect of new non-vasoconstrictor treatments for migraine and cluster headache.

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • Peter J. Goadsby
    • 1
  1. 1.Institute of NeurologyLondonUK

Personalised recommendations